Japan and Singapore forge biomaterials deal:
This article was originally published in Clinica
The Japanese National Institute for Materials Science and the National University of Singapore last month signed memorandum to collaborate in the field of biomaterials research. Under the agreement, both sides will exchange information and share technology for the designing and processing of biomaterials. The aim is to commercialise new products for advanced medical treatment. The memorandum is part of the Japan-Singapore Economic Agreement, concluded in January 2002, contained within the New Age Partnership, which also includes a bilateral trade agreement, reports Japan Chemical Week.
You may also be interested in...
EU Regulatory Roundup, February 2020: Brexit And Swixit Threaten Huge Disruption Amidst MDR Uncertainty
Complying with the EU’s new Medical Device Regulation would be hard enough. But more layers of uncertainty – especially Brexit and Swixit ̶ mean European medtech is navigating very turbulent waters right now.
Fresenius Kabi has reported sales ahead by 6% in 2019, as growth in emerging markets helped to offset a subdued increase in North America. Meanwhile, the firm has pushed back financial expectations for its biosimilars by a year.
Fresenius Kabi and Vifor Pharma have agreed to create a joint venture in China for intravenous iron products.